Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates

Tumor Biology

Volumn 20, Issue 4, 1999, Pages 218-224

  Lutsenko, S V ^a   Feldman, N B ^b   Finakova, G V ^b   Posypanova, G A ^a   Severin, S E ^b   Skryabin, K G ^a   Kirpichnikov, M P ^a   Lukyanets, E A ^c   Vorozhtsov, G N ^c  

^a INSTITUTE OF BIOENGINEERING   (Russian Federation)

^b Moscow Research Institute of Medical Ecology   (Russian Federation)

^c Organic Intermediates and Dyes Institute   (Russian Federation)

Author keywords

Conjugate; Disulfochloride aluminum phthalocyanine; Disulfochloride cobalt phthalocyanine; Epidermal growth factor; Phthalocyanines; Targeted delivery

Indexed keywords

EPIDERMAL GROWTH FACTOR; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE COBALT; PHTHALOCYANINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER CELL DESTRUCTION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

EID: 0033053950     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030066     Document Type: Article

References (15)

1. Liao C-W, Hseu TH, Hwang J: A target-specific chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain. Appl Microbiol Biotechnol 1995;43:498-507.
2. Severin SE, Moskaleva EYu, Posypanova GA, Koromyslova IA, Shmyrev II, Krivonos AV, Myagkikh IV, Feldman NB, Finakova GV, Katukov VYu, Luzhkov YuM, Nakachian R, Andreani J, Severin ES: In vivo antitumor activity of cytoxic drugs conjugated with hu man α-fetoprotein. Tumor Targeting 1996;2:299-306.
3. Hellstrom I, Hellstrom KE, Siegall CB, Trail PA: Immunoconjugates and immunotoxins for therapy of carcinomas. Adv Pharmacol 1995; 33:349-388.
4. Stumm G, Eberwein S, Rostock-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R: Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996; 69:17-22.
5. Tokunada A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995;75: 1418-1425.
6. Severin SE, Moskaleva EYu, Shmyrev II, Posypanova GA, Belousova YuV, Sologub VK, Luzhkov YuM, Nakachian R, Andreani J, Severin ES: Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro. Biochem Mol Biol Int 1995;2:385-392.
7. Modjtahedi H, Dean Ch: The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int J Oncol 1995; 4:277-296.
8. Van Hillegersberg R, Kort WJ, Wilson JM: Current status of photodynamic therapy in oncology. Drugs 1994;48:510-527.
9. Novodarova GN, Belkov VM, Vol'pin ME, Shaharova ZA: The activator of dioxygen and the homogeneous catalytic oxidation. 6th Int Symp, Noordwijkerhout, 1996, pp 215-216.
10. PCT/RU 96/00060, 17.07.95. Positive decision on application 95112240/14dtd. 30.05.96.
11. Savage CR, Cohen J: Epidermal growth factor and a new derivative: Rapid isolation procedures and biological and chemical characterization. J Biol Chem 1972;247:7609-7611.
12. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
13. Huang TW, Rauth S, Das Gupta TK: Overexpression of EGF receptor is associated with spontaneous metastases of a human melanoma cell line in nude mice. Anticancer Res 1996;16:3557-3564.
14. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Rosemary S, Herlin M: Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989;49:5091-5096.
15. Holzmann B, Broecker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmueller C, Johnson JR: Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-471.